PharmacoEconomics & Outcomes News

, Volume 531, Issue 1, pp 10–10 | Cite as

Cyclophosphamide improves QOL in scleroderma lung disorder

Clinical study


Cyclophosphamide Mental Component Summary Health Assessment Questionnaire Mental Component Summary Score Health Assessment Questionnaire Disability Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ, Scleroderma Lung Study Group.Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis and Rheumatism 56: 1676-1684, No. 5, May 2007Google Scholar

Copyright information

© Adis International Ltd 2007

Personalised recommendations